sorbitol and canagliflozin

sorbitol has been researched along with canagliflozin in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Chung, SH; Kim, GW1
Castellino, P; Fatuzzo, P; Granata, A; Lentini, P; Rapisarda, F; Rastelli, S; Zanoli, L1
Shyangdan, DS; Uthman, OA; Waugh, N1
Imamura, M; Kurosaki, E; Tahara, A; Takasu, T; Yokono, M1
Kishimoto, M; Ohta, M; Suzuki, H; Takenaka, T; Tomonaga, O1
Inoue, D; Inoue, R; Nangaku, M; Nishi, H1

Reviews

3 review(s) available for sorbitol and canagliflozin

ArticleYear
Clinical implication of SGLT2 inhibitors in type 2 diabetes.
    Archives of pharmacal research, 2014, Volume: 37, Issue:8

    Topics: Administration, Oral; Benzhydryl Compounds; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes

2014
Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.
    TheScientificWorldJournal, 2015, Volume: 2015

    Topics: Animals; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol

2015
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
    BMJ open, 2016, Feb-24, Volume: 6, Issue:2

    Topics: Bayes Theorem; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Weight Loss

2016

Other Studies

3 other study(ies) available for sorbitol and canagliflozin

ArticleYear
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
    Journal of pharmacological sciences, 2016, Volume: 130, Issue:3

    Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Mice, Inbred ICR; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes; Tissue Distribution

2016
Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy.
    Diabetes & vascular disease research, 2017, Volume: 14, Issue:3

    Topics: Albuminuria; Biomarkers; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Canagliflozin; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Male; Medical Records; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Time Factors; Treatment Outcome

2017
Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan.
    International heart journal, 2021, Volume: 62, Issue:3

    Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiologists; Cardiovascular System; Data Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Kidney; Male; Prescriptions; Regression Analysis; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes

2021